[go: up one dir, main page]

EP1289551A4 - HUMAN POLYPEPTIDES THAT LEAD TO THE DISAPPEARANCE OF CELLS, IN PARTICULAR LYMPHOID TUMOR CELLS - Google Patents

HUMAN POLYPEPTIDES THAT LEAD TO THE DISAPPEARANCE OF CELLS, IN PARTICULAR LYMPHOID TUMOR CELLS

Info

Publication number
EP1289551A4
EP1289551A4 EP01935513A EP01935513A EP1289551A4 EP 1289551 A4 EP1289551 A4 EP 1289551A4 EP 01935513 A EP01935513 A EP 01935513A EP 01935513 A EP01935513 A EP 01935513A EP 1289551 A4 EP1289551 A4 EP 1289551A4
Authority
EP
European Patent Office
Prior art keywords
cells
proteins
peptides
disappearance
lead
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01935513A
Other languages
German (de)
French (fr)
Other versions
EP1289551A1 (en
Inventor
Zoltan Nagy
Christoph Brunner
Michael Tesar
Elisabeth Thomassen-Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys AG
Agennix AG
Original Assignee
Morphosys AG
Agennix AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys AG, Agennix AG filed Critical Morphosys AG
Priority to EP01935513A priority Critical patent/EP1289551A4/en
Publication of EP1289551A1 publication Critical patent/EP1289551A1/en
Publication of EP1289551A4 publication Critical patent/EP1289551A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells. The invention further relates to nucleic acids encoding the peptides/proteins, methods for the production of the peptides/proteins, methods for killing cells, pharmaceutical, diagnostic and multivalent compositions and kits comprising the peptides/proteins and uses of the peptides/proteins. <IMAGE>
EP01935513A 2000-05-12 2001-05-14 HUMAN POLYPEPTIDES THAT LEAD TO THE DISAPPEARANCE OF CELLS, IN PARTICULAR LYMPHOID TUMOR CELLS Withdrawn EP1289551A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP01935513A EP1289551A4 (en) 2000-05-12 2001-05-14 HUMAN POLYPEPTIDES THAT LEAD TO THE DISAPPEARANCE OF CELLS, IN PARTICULAR LYMPHOID TUMOR CELLS

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP00110065 2000-05-12
EP00110065A EP1156060B1 (en) 2000-05-12 2000-05-12 Human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells
US23849200P 2000-10-06 2000-10-06
US238492P 2000-10-06
EP01935513A EP1289551A4 (en) 2000-05-12 2001-05-14 HUMAN POLYPEPTIDES THAT LEAD TO THE DISAPPEARANCE OF CELLS, IN PARTICULAR LYMPHOID TUMOR CELLS
PCT/US2001/015625 WO2001087337A1 (en) 2000-05-12 2001-05-14 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells

Publications (2)

Publication Number Publication Date
EP1289551A1 EP1289551A1 (en) 2003-03-12
EP1289551A4 true EP1289551A4 (en) 2009-06-10

Family

ID=8168691

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00110065A Expired - Lifetime EP1156060B1 (en) 2000-05-12 2000-05-12 Human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells
EP01935513A Withdrawn EP1289551A4 (en) 2000-05-12 2001-05-14 HUMAN POLYPEPTIDES THAT LEAD TO THE DISAPPEARANCE OF CELLS, IN PARTICULAR LYMPHOID TUMOR CELLS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP00110065A Expired - Lifetime EP1156060B1 (en) 2000-05-12 2000-05-12 Human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells

Country Status (10)

Country Link
EP (2) EP1156060B1 (en)
JP (1) JP2004515214A (en)
CN (1) CN1607959A (en)
AT (1) ATE365749T1 (en)
AU (3) AU6160201A (en)
CA (1) CA2408360A1 (en)
DE (1) DE60035337T2 (en)
HK (1) HK1053985A1 (en)
RU (1) RU2004121673A (en)
WO (1) WO2001087337A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
ATE391174T1 (en) 2000-10-20 2008-04-15 Chugai Pharmaceutical Co Ltd MODIFIED TPO AGONIST ANTIBODY
CA2452986C (en) * 2001-07-02 2011-11-01 Aimsco Limited Use of polyclonal anti-hiv goat serum as a therapeutic agent
CN1571797A (en) 2001-10-15 2005-01-26 麒麟麦酒株式会社 Anti-hla-dr antibody
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
AU2002950658A0 (en) * 2002-08-08 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
JP2004279086A (en) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc Radiation image conversion panel and method for manufacturing it
WO2005023299A2 (en) * 2003-09-09 2005-03-17 Gpc Biotech Ag Therapeutic human anti-mhc class ii antibodies and their uses
WO2005058251A2 (en) * 2003-12-15 2005-06-30 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
CA2553257A1 (en) 2004-01-14 2005-08-04 Ohio University Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
EP1751177A4 (en) * 2004-04-19 2008-07-16 Univ Ohio Cross-linkable glycoproteins and methods of making the same
ES2327840T3 (en) 2004-12-23 2009-11-04 Gpc Biotech Ag DERIVATIVES OF ESCUARIC ACID WITH ANTIPROLIFERATIVE ACTIVITY.
WO2006089232A2 (en) * 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against cd30 lacking fucosyl residues
EP2351842A1 (en) 2005-03-25 2011-08-03 National Research Council Of Canada Method for isolation of soluble polypeptides
WO2006106903A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
WO2006123724A1 (en) * 2005-05-18 2006-11-23 The University Of Tokushima Novel pharmaceutical using anti-hla antibody
JP5085322B2 (en) 2005-06-10 2012-11-28 中外製薬株式会社 Pharmaceutical composition containing sc (Fv) 2
JP5068167B2 (en) 2005-06-10 2012-11-07 中外製薬株式会社 Stabilizer for protein preparation containing meglumine and use thereof
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
EP2019101A1 (en) 2007-07-26 2009-01-28 GPC Biotech AG Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
JP5774595B2 (en) 2009-10-28 2015-09-09 ヤンセン バイオテツク，インコーポレーテツド Anti-GLP-1R antibodies and their use
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
JP5884139B2 (en) * 2010-10-04 2016-03-15 国立研究開発法人理化学研究所 Therapeutic agent for malignant tumors expressing MHC class II
RU2011122942A (en) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" NEW KINAZ INHIBITORS
CN102435728B (en) * 2011-09-07 2014-06-25 福州大学 Preparation method for positive control substance for inspection and control of quality in immunohistochemical process
CN110191952A (en) 2016-10-07 2019-08-30 瑟卡尔纳制药有限公司 The new method for the treatment of cancer
CN107353344B (en) * 2017-07-07 2019-10-25 南通大学 A polypeptide capable of specifically killing activated B-cell diffuse large B-cell lymphoma and its application
CN114231551B (en) * 2021-12-24 2023-09-29 云南大学 Application of protein in promoting apoptosis of insect lymphocytes and/or preventing and controlling pests

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017874A1 (en) * 1994-12-07 1996-06-13 F. Hoffmann-La Roche Ag Monoclonal antibody fragments having immunosuppressant activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2322749A1 (en) * 1998-03-03 1999-09-10 Abgenix, Inc. Cd147 binding molecules as therapeutics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017874A1 (en) * 1994-12-07 1996-06-13 F. Hoffmann-La Roche Ag Monoclonal antibody fragments having immunosuppressant activity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A. KNAPPIK ET AL.: "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.", JOURNAL OF MOLECULAR BIOLOGY, vol. 296, 2000, pages 57 - 86, XP004461525 *
D. VIDOVIC ET AL.: "Down-regulation of class II major histocompatibility complex molecules on antigen-presenting cells by antibody fragments.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 25, no. 12, December 1995 (1995-12-01), Weinheim, Germany, pages 3349 - 3355, XP000564479 *
D. VIDOVIC ET AL.: "Selective apoptosis of neoplastic cells by the HLA-DR-specific monoclonal antibody.", CANCER LETTERS, vol. 128, 1998, pages 127 - 135, XP002944554 *
H. VIKEN ET AL.: "Serologic subtyping of HLA-DR8 by means of the cytotoxic human monoclonal antibody 5643.", HUMAN IMMUNOLOGY, vol. 43, no. 3, July 1995 (1995-07-01), USA, pages 200 - 206, XP000939101 *
H. VIKEN ET AL.: "The cytotoxic HLA-DQ3 reactive human hybridoma antibody 4166 that may distinguish DQ7+8 from DQ9.", HUMAN IMMUNOLOGY, vol. 42, no. 4, 1995, USA, pages 281 - 288, XP002525019 *
R. EFROS ET AL.: "A human-human hybridoma secreting anti-HLA class II antibody.", THE JOURNAL OF IMMUNOLOGY, vol. 137, no. 5, 1 September 1986 (1986-09-01), Baltimore, MD, USA, pages 1599 - 1603, XP002525020 *

Also Published As

Publication number Publication date
EP1289551A1 (en) 2003-03-12
EP1156060A1 (en) 2001-11-21
WO2001087337A1 (en) 2001-11-22
AU2006225244A1 (en) 2006-10-26
JP2004515214A (en) 2004-05-27
AU2001261602B2 (en) 2006-07-06
DE60035337D1 (en) 2007-08-09
RU2004121673A (en) 2006-01-10
ATE365749T1 (en) 2007-07-15
HK1053985A1 (en) 2003-11-14
EP1156060B1 (en) 2007-06-27
CA2408360A1 (en) 2001-11-22
DE60035337T2 (en) 2008-02-28
CN1607959A (en) 2005-04-20
AU6160201A (en) 2001-11-26

Similar Documents

Publication Publication Date Title
EP1289551A4 (en) HUMAN POLYPEPTIDES THAT LEAD TO THE DISAPPEARANCE OF CELLS, IN PARTICULAR LYMPHOID TUMOR CELLS
EA200901129A1 (en) NUCLEIC ACIDS AND POLYPEPTIDES OF THE NEW RECEPTOR
CY1118443T1 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
ATE352559T1 (en) METHOD FOR REDUCING THE IMMUNOGENICITY OF PROTEINS
ATE516304T1 (en) NRG-2 NUCLEIC ACIDS, POLYPEPTIDES AND DIAGNOSTIC/THERAPEUTIC METHODS
DE60033293D1 (en) NEW B7-4 MOLECULES AND THEIR USES
MX344216B (en) Genetic products differentially expressed in tumors and the use thereof.
EP2298355A3 (en) Albumin fusion proteins
EA200200755A1 (en) MEDIATED BY NOGO RECEPTOR OF AXON GROWTH BLOCKADE
WO2002050277A3 (en) Protein and nucleic acids encoding same
ATE358716T1 (en) POLYPEPTIDES FOR TRIGGERING AN IMMUNE RESPONSE AGAINST CANCER
HUP0100267A2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
ATE506370T1 (en) REAGENTS AND METHODS FOR FORMING DISULFIDE BONDS AND GLYCOSYLATION OF PROTEINS
HK1046648B (en) Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
WO2001043693A3 (en) Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
DE60140559D1 (en) 32144, A HUMAN FATTY ACID HYDROLASE AND ITS USES
WO2001092493A3 (en) 21956 and 25856, human aminopeptidases and uses thereof
DE60142356D1 (en) 18480 HUMAN PROTEIN KINASEMOLEKÜLE AND ITS USES
WO2001090187A3 (en) G-protein coupled olfactory receptors
WO2002026985A3 (en) G-protein coupled recptors
DE60129228D1 (en) HUMANE 7-TRANSMEMBRANE PROTEINS AND POLYNUCLEOTIDE CODING THEREFOR
CA2405084A1 (en) Neutralizing immunogenic hev polypeptides
ITMI20041965A1 (en) &#34;CODIFYING DYNAMIC AND CHEMICAL FORMS OF PROTEIN P185NEU AND ITS THERAPEUTIC USES&#34;
DE60139153D1 (en) 14189, A HUMAN KINASE AND ITS USES
WO2001060844A3 (en) Peptide and nucleic acid coding therefor for the detection, diagnosis and therapy of diseases of the nervous system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: THOMASSEN-WOLF, ELISABETH

Inventor name: TESAR, MICHAEL

Inventor name: BRUNNER, CHRISTOPH

Inventor name: NAGY, ZOLTAN

RIN1 Information on inventor provided before grant (corrected)

Inventor name: THOMASSEN-WOLF, ELISABETH

Inventor name: TESAR, MICHAEL

Inventor name: BRUNNER, CHRISTOPH

Inventor name: NAGY, ZOLTAN

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/00 20060101ALN20090428BHEP

Ipc: G01N 33/53 20060101ALI20090428BHEP

Ipc: A61K 39/44 20060101ALI20090428BHEP

Ipc: A61K 39/395 20060101ALI20090428BHEP

Ipc: C07K 16/28 20060101AFI20090428BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090512

17Q First examination report despatched

Effective date: 20090921

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100202

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1053985

Country of ref document: HK